Opioid addiction has become an epidemic in the U.S. in the past decade and yet, only a few medicines are in development for its treatment. That is why Segal Institute for Clinical Research is proud to have three Principal Investigators currently participating in Braeburn Pharmaceuticals and Camurus’ Phase 3 efficacy Trial of Long-acting Treatment for Opioid Dependence. This randomized, double blind, active-controlled Phase 3 trial is part of the registration program for CAM2038 that also includes a Phase 2 opioid blockade study and a long-term safety trial.
For more on the trial Please read below. http://www.businesswire.com/news/home/20160113005917/en
